Actively Recruiting
Phase 2 Study of Safety and Immune Response to Rift Valley Fever Vaccine TSI-GSD 200 in Adults at Risk of Exposure
Led by U.S. Army Medical Research and Development Command · Updated on 2021-02-11
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of a Rift Valley Fever RVF vaccine called TSI-GSD 200, Lot 7, Run 2. This phase 2 study focuses on adults aged 18 to 65 who are at risk of exposure to the RVF virus, either by working in research areas where the virus is used or living in regions where the disease is common. The goal is to collect important data on how well the vaccine triggers an immune response and what side effects may occur. Participants will receive the RVF vaccine as a 1.0 mL dose injected under the skin in the upper outer arm. The study includes individuals who show a certain level of immune response titer >140 and involves follow-up visits to monitor their condition. The vaccine is given as a biological treatment, and the study does not involve blinding or placebo controls. Throughout the study, participants will be monitored for local and systemic adverse events within 28 days after each vaccine dose. Blood tests will measure immune response levels 21 to 35 days after vaccination and again at month 12. Researchers will also track the frequency and severity of side effects and measure specific antibody levels. Participants must agree to report all adverse events and attend follow-up visits for about one year after vaccination to ensure safety and collect complete data.
CONDITIONS
Brief Title
Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
Research Team
A
Anthony P Cardile, DO, MAJ
J
Jeannine M Haller, RN, CCRP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here